|
Neihu, Taiwan (July 31, 2018)
Abnova announced today that it is launching a new cell-based, non-invasive liquid biopsy of circulating endothelial progenitor cells (EPC) for the healthy and anti-aging markets. Abnova has established successful rare cell enrichment platforms targeting circulating tumor cells (CTCs) for the cancer patients and circulating fetal cells (CFCs) for the expectant mothers. In contrast, circulating EPCs specifically address the state and well-being of the regenerative endothelial cells in both healthy and aging individuals. A higher level of circulating EPCs is protective of the body’s vascular network against aging, cardiac and vascular diseases1. Traditional circulating EPCs detection by flow cytometry is handicapped by low sensitivity, high variability, and complex operation when measuring such rare cell population2. On the other hand, Abnova’s more advanced yet simpler cell enrichment platform combined with CD34+/KDR+ and CD133+/KDR+ monoclonal antibodies is better suited for the detection of rare circulating EPCs. Going forward, Abnova will be providing circulating EPC testing service through its own clinical laboratory Wellconn Genomics in Taiwan and Abnova Diagnostics in Japan targeting the healthy and anti-aging markets.
“We are living in a highly health-conscious society. Also, with increased life expectancy, we are already seeing a large increase in the aging population worldwide. These two drivers are setting precedence for new markets demanding novel and unmet products and services” said, Dr. Wilber Huang, President of Abnova Corporation. “The market interest in circulating EPCs has increased in recent years. We want to be the first mover and a competitive player in the new field of cell-based, non-invasive liquid biopsy pertaining to circulating EPC detection, with highly sensitive, accurate and real-time measurement. By leveraging our enrichment technologies and antibody capability, we continue to identify new markets which will bring long-term value to our rare cell platforms and the company.”
Circulating EPCs originates from the bone marrow. While the bone marrow EPCs are relatively constant, the circulating EPCs decrease with age and disease. A key hallmark of aging and aging-associated health decline is the loss of endothelial function. The endothelium plays several functions essential for life, including acting as an barrier between blood stream and interior of the blood vessels, allowing migration of cells into and out of the blood stream, regulating blood flow through controlling smooth muscle contraction, participating in tissue remodeling. The idea that aging is irreversible is an old-school. Aging can be reversed by effective life-style changes including diet, exercise, and validated supplements3, as evidenced by the improved levels of circulating EPCs in our bloodstream.
|
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)